M
Margaret Skokan
Researcher at University of Colorado Boulder
Publications - 18
Citations - 1935
Margaret Skokan is an academic researcher from University of Colorado Boulder. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 13, co-authored 18 publications receiving 1823 citations. Previous affiliations of Margaret Skokan include Case Western Reserve University & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
Federico Cappuzzo,Antonio Marchetti,Margaret Skokan,Elisa Rossi,Sujatha Gajapathy,Lara Felicioni,Maela Del Grammastro,Maria Grazia Sciarrotta,F Buttitta,Matteo Incarbone,Luca Toschi,Giovanna Finocchiaro,Annarita Destro,Luigi Terracciano,Massimo Roncalli,Marco Alloisio,Armando Santoro,M. Varella-Garcia +17 more
TL;DR: MET increased gene copy number is an independent negative prognostic factor in surgically resected NSCLC and EGFR gene gain does not impact survival after resection.
Journal ArticleDOI
Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Kurtis D. Davies,Anh T. Le,Mariana F. Theodoro,Margaret Skokan,Dara L. Aisner,Eamon M. Berge,Luigi Terracciano,Federico Cappuzzo,Matteo Incarbone,Massimo Roncalli,Marco Alloisio,Armando Santoro,D. Ross Camidge,Marileila Varella-Garcia,Robert C. Doebele +14 more
TL;DR: ROS1 inhibition may be an effective treatment strategy for the subset of patients with NSCLC whose tumors express ROS1 fusion genes, and this patient showed tumor shrinkage upon treatment with crizotinib.
Journal ArticleDOI
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
Federico Cappuzzo,Pasi A. Jänne,Margaret Skokan,Giovanna Finocchiaro,Elisa Rossi,C. Ligorio,Paolo Andrea Zucali,Luigi Terracciano,Luca Toschi,Massimo Roncalli,Annarita Destro,Matteo Incarbone,Marco Alloisio,Armando Santoro,Marileila Varella-Garcia +14 more
TL;DR: In this article, the MET gene copy number was analyzed using FISH in two related non-small-cell lung cancer cell lines, one sensitive (HCC827) and one resistant to gefitinib therapy and in two different NSCLC patient populations.
Journal ArticleDOI
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
Federico Cappuzzo,Marileila Varella-Garcia,Gaetano Finocchiaro,Gaetano Finocchiaro,Margaret Skokan,Sujatha Gajapathy,C. Carnaghi,Lorenza Rimassa,Elisa Rossi,C. Ligorio,C. Ligorio,L. Di Tommaso,Alison J. Holmes,Luca Toschi,Giovanni Tallini,Annarita Destro,Massimo Roncalli,Armando Santoro,Pasi A. Jänne +18 more
TL;DR: KRAS mutations are associated with cetuximab failure in EGFR FISH+ mCRC, even if it does not preclude response, and the rarity of MET and IGF1R gene amplification suggests a marginal role in primary resistance.
Journal ArticleDOI
Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
D. Ross Camidge,Mariana F. Theodoro,DeLee A. Maxson,Margaret Skokan,Terence J. O'Brien,Xian Lu,Robert C. Doebele,Anna E. Barón,Marileila Varella-Garcia +8 more
TL;DR: In this article, the authors explored correlations between the percentage of ALK+ cells and signal copy number and their association with response to ALK inhibition and found that the strong association between increased copy number of key ALK signals and percentage of positive cells suggests that the <100% rate of cellular positivity in ALK-positive (ALK+) nonsmall cell lung cancer (NSCLC) is due to technical factors, not biological factors.